1. Home
  2. CANF vs ECPG Comparison

CANF vs ECPG Comparison

Compare CANF & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

N/A

Current Price

$2.22

Market Cap

6.7M

Sector

Health Care

ML Signal

N/A

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

N/A

Current Price

$94.17

Market Cap

2.0B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CANF
ECPG
Founded
1994
1998
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
2.0B
IPO Year
2011
1999

Fundamental Metrics

Financial Performance
Metric
CANF
ECPG
Price
$2.22
$94.17
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $115.67
AVG Volume (30 Days)
212.7K
★ 291.0K
Earning Date
09-08-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 287.14
EPS
N/A
★ 6.66
Revenue
N/A
★ $1,768,802,000.00
Revenue This Year
N/A
$8.01
Revenue Next Year
N/A
$1.35
P/E Ratio
★ N/A
$14.33
Revenue Growth
N/A
★ 34.37
52 Week Low
$0.17
$39.95
52 Week High
$10.40
$104.98

Technical Indicators

Market Signals
Indicator
CANF
ECPG
Relative Strength Index (RSI) 38.34 43.26
Support Level $2.16 $93.16
Resistance Level $2.39 $103.30
Average True Range (ATR) 0.07 2.84
MACD 0.04 -0.56
Stochastic Oscillator 44.00 12.86

Price Performance

Historical Comparison
CANF
ECPG

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.

Share on Social Networks: